Tesamorelin
Typical Dosage
1-2 mg/day
Administration
Injection
Half-Life
26-38 minutes
Mechanism of Action
HIV-associated lipodystrophy research|Visceral-fat reduction|GH axis studies|NAFLD and body-composition research
Research Protocol Summary
Evidence Level
Human Clinical / Marketed
Typical Protocol Duration
6-12 weeks
Species Studied
Human
Administration Schedule
Daily, Fasted
Timing Notes
Fasted
Studies
Research Availability
Individual PubMed records have not been mapped for this entry yet. Use the linked PubMed search to review the current literature directly.
Related resources
Research Feedback
0 approved
For research discussion only. Community feedback is moderated and shown here as aggregated insights after approval.
Loading approved insights…